Low Libido (Reduced Sex Drive) — Causes, Diagnosis & Treatment Guide — Symptoms, Causes & Treatment | MyMedicPlus

Libido (sexual desire or sex drive) refers to the overall interest in or motivation for sexual activity. Low libido — medically termed hypoactive sexual desire disorder (HSDD) or more recently female sexual interest/arousal disorder (FSIAD) in women — is a persistent or recurring deficiency or absence of sexual fantasies and desire for sexual activity that causes personal distress or interpersonal difficulty. HSDD is the most common female sexual dysfunction. Libido is a multidimensional concept influenced by physiological (hormonal), psychological, relational, and contextual factors — a biopsychosocial model of sexual desire is essential for understanding and treating low libido. Sexual desire normally varies widely between individuals and across life stages — there is no 'normal' level of libido. A significant, persistent change from an individual's baseline that causes personal distress is the clinically relevant criterion, not a comparison to population norms. Low libido affects approximately 20-40% of women and 15-25% of men at any given time; prevalence increases significantly with age, menopause, depression, and chronic illness. In the Global Study of Sexual Attitudes and Behaviors (GSSAB), approximately 30-40% of women reported low sexual desire — it is one of the most common reasons for seeking help from a GP, psychosexual therapist, or gynaecologist.

Low libido has multiple potential causes, often interacting, that must be systematically assessed. Hormonal causes: testosterone deficiency in men (hypogonadism — low libido is one of the earliest symptoms; however testosterone deficiency alone rarely explains all cases of low libido, and relationship and psychological factors are co-determinants); in women, testosterone levels decline significantly after menopause and oophorectomy (surgical removal of ovaries — surgical menopause causes more abrupt testosterone fall than natural menopause); oestrogen deficiency in perimenopause and menopause (causes genito-urinary syndrome — vaginal dryness, dyspareunia — which itself inhibits sexual desire); hyperprolactinaemia (prolactin excess — from pituitary adenoma, antipsychotics, metoclopramide — suppresses GnRH and sex steroid production in both men and women); thyroid dysfunction (hypothyroidism and hyperthyroidism both impair libido); and adrenal insufficiency. Psychological causes (frequently the most important): depression (one of the most powerful suppressants of sexual desire — and antidepressants used to treat depression are themselves a major cause of SSRI-related low libido); anxiety; chronic stress; negative body image; sexual trauma history (PTSD); and performance anxiety. Relationship factors: relationship conflict, communication breakdown, loss of intimacy, partner sexual dysfunction, infidelity, and power imbalances frequently cause low libido in one or both partners — the most prevalent and important context for low libido in otherwise healthy adults. Medication causes (extremely common and often overlooked): SSRIs and SNRIs (sertraline, fluoxetine, venlafaxine — cause significant libido reduction in 30-40% of users — the most common medication cause); antipsychotics (via hyperprolactinaemia); combined oral contraceptive pill (lowers free testosterone by raising SHBG — affects approximately 15% of pill users); anti-androgens (spironolactone, finasteride, bicalutamide); opioids (suppress hypothalamic GnRH); and beta-blockers. Medical conditions: chronic pain, fatigue, and illness reduce libido non-specifically; cardiovascular disease, diabetes, and obesity impair sexual function through vascular and hormonal mechanisms; sleep disorders (sleep deprivation dramatically reduces testosterone in men); alcohol and recreational drugs (acute alcohol reduces sexual inhibition but chronic heavy use suppresses testosterone and causes erectile dysfunction).

Low libido presents as: reduced or absent interest in sexual activity (spontaneous sexual desire — fantasies, thoughts about sex — is diminished or absent); reduced or absent receptive desire (interest in sex when the partner initiates — may still respond with arousal when sexual contact occurs, but interest does not arise spontaneously); and personal distress from the change in sexual desire. Associated features that help identify underlying causes: in women — vaginal dryness, painful intercourse (dyspareunia), reduced genital sensitivity (pointing to oestrogen deficiency or GSMD); in men — erectile dysfunction combined with low libido (pointing to low testosterone, depression, or cardiovascular risk); mood changes (depression, irritability — pointing to mood disorder or hormonal cause); fatigue (pointing to thyroid dysfunction, anaemia, sleep disorder, or depression); and relationship conflict (relational context — frequently both cause and consequence of low libido). Impact assessment: HSDD causes significant distress — reduced quality of life, relationship strain, partner dissatisfaction, anxiety about sexual performance, reduced self-esteem, and relationship dissolution. The Female Sexual Function Index (FSFI) and its desire subscale; the Sexual Interest and Desire Inventory — Female (SIDI-F); and the Male Sexual Health Questionnaire — Shortened (MSHQ-SD) quantify sexual dysfunction severity. Spontaneous vs responsive desire: clinicians should assess both — many women have predominantly responsive desire (arousal occurs in response to stimulation rather than arising spontaneously) — this is a normal variant, not pathological, and its absence does not indicate HSDD unless there is personal distress.

Low libido is a clinical diagnosis requiring thorough history — sexual history, medical history, medication review, and relationship assessment. Sexual history: duration and severity of low libido; whether it is situational (only with partner — may suggest relationship factors or partner sexual dysfunction) or generalised (with all partners and during masturbation — more likely biological cause); any preceding trigger; impact on wellbeing and relationship; history of sexual trauma or abuse; past sexual satisfaction. Medical history: current medications (SSRIs, OCP, antipsychotics, opioids, beta-blockers — all major causes); chronic illnesses; surgical history (oophorectomy, prostatectomy); symptoms of depression, anxiety, or PTSD; menopausal status and symptoms (women); and relationship quality. Investigations to identify treatable causes: in both sexes: thyroid function (TSH), prolactin, full blood count, fasting glucose, sex hormone binding globulin (SHBG); in men: total testosterone (two morning fasting samples), LH, FSH (to classify hypogonadism); in women: FSH, oestradiol (menopausal status), testosterone (total and free — although assay reliability is limited at low female concentrations); total and free testosterone and SHBG. Depression screening: PHQ-9. Relationship assessment: may require referral for couples therapy or psychosexual assessment. Partner factors: partner sexual dysfunction (erectile dysfunction, premature ejaculation) frequently causes reactive low libido in the other partner.

Treatment is cause-directed and multidisciplinary. Address medication causes: consider switching SSRIs to bupropion (an NDRI with lowest sexual side effects of all antidepressants) or mirtazapine (no serotonergic mechanism — fewer sexual side effects); reduce SSRI dose or take drug holidays (caution re: relapse); consider sildenafil for antidepressant-induced sexual dysfunction (augmentation); switch OCP (oral contraceptive pill) to a different preparation or alternative method; reduce or stop opioids where clinically possible. Hormonal treatment: testosterone for women with HSDD (post-menopause, surgical menopause, or post-oophorectomy — best evidence for testosterone supplementation in women — meta-analyses demonstrate significant improvement in sexual desire, arousal, and satisfaction with testosterone gel or cream applied topically; the BSSMand Endocrine Society recommend testosterone for postmenopausal women with HSDD where other causes have been addressed — dose target is the upper physiological premenopausal range); oestrogen therapy (local vaginal oestrogen for GSMD/dyspareunia — dramatically improves libido by relieving painful sex; systemic HRT reduces menopausal symptoms including libido loss); testosterone for men (only for confirmed biochemical hypogonadism with symptoms — see low testosterone topic); correct hypothyroidism, hyperprolactinaemia, and other hormonal disturbances. Pharmacological options specific to HSDD: Flibanserin (Addyi — 100mg daily at bedtime — FDA approved for premenopausal women with HSDD — serotonin 5-HT1A agonist and 5-HT2A antagonist — mixed CNS mechanism; modest but significant improvement in sexual desire — mean increase of 0.5 satisfying sexual events per month; side effects: hypotension with alcohol, dizziness, somnolence — requires avoiding alcohol for 2 hours before bedtime dose). Bremelanotide (Vyleesi — subcutaneous self-injection 45 minutes before anticipated sexual activity — FDA approved 2019 — melanocortin receptor agonist activating sexual desire pathways in the brain; significant improvement in sexual desire scores; side effects: nausea in 40%, flushing, BP increase). Psychosexual therapy: CBT-based sex therapy (directed exercises — sensate focus, communication training, mindfulness); couples therapy; trauma-informed therapy for sexual trauma history; relationship counselling. Lifestyle: regular aerobic exercise increases testosterone and dopamine; weight management; limit alcohol; optimise sleep. Mindfulness-based sexual therapy specifically for HSDD in women has Level I evidence.

Untreated or chronically low libido causes significant personal, relational, and psychological complications. Relationship impact: sexual dissatisfaction is a leading cause of relationship distress and breakdown — partners may interpret low libido as rejection or loss of attraction, leading to increasing conflict, emotional distance, and avoidance of intimacy beyond sexual contact; couples therapy is often required alongside individual treatment. Psychological complications: when libido loss is distressing (meeting the diagnostic threshold for HSDD), associated depression, reduced self-esteem, shame, guilt, and anxiety about sexual performance are common — a bidirectional relationship exists where low libido worsens mood and mood further worsens libido. Delays in diagnosing underlying conditions: many individuals fail to report libido concerns to healthcare providers due to embarrassment or normalisation, leading to diagnostic delays for treatable conditions including hypogonadism, hypothyroidism, depression, hyperprolactinaemia, and medication side effects. Hypogonadism complications if untreated: in men — osteoporosis, muscle mass reduction (sarcopaenia), anaemia, and metabolic syndrome; in women — vulvovaginal atrophy, genitourinary syndrome of menopause, cardiovascular disease risk, and osteoporosis from oestrogen deficiency. Treatment complications: testosterone therapy without confirmed biochemical deficiency carries risks of erythrocytosis (elevated haematocrit and thromboembolism), suppression of endogenous testicular function, mood lability, and acne; hormonal treatment should be reserved for confirmed deficiency states. Sexual trauma sequelae: low libido as a consequence of unacknowledged or untreated sexual trauma requires trauma-informed therapy — standard libido treatments are often ineffective and potentially retraumatising without addressing the underlying psychological cause first.

Sexual health maintenance requires proactive attention to physical, psychological, and relational factors. Discuss sexual side effects with prescribing clinicians when starting new medications (SSRIs, antipsychotics, OCP, opioids, beta-blockers) — alternatives or strategies can be planned proactively. Maintain regular, open communication with a sexual partner about needs, desires, and concerns — relationship satisfaction is the strongest predictor of sexual wellbeing. Treat depression and anxiety promptly and comprehensively — including addressing sexual side effects of antidepressants with the prescribing clinician. For women approaching menopause: proactive discussion of GSMD (genito-urinary syndrome of menopause) and HRT options with a GP or menopause specialist before libido declines severely. For men: regular exercise, healthy weight, cardiovascular risk management, and testosterone monitoring from age 45 in high-risk groups (obesity, diabetes, sleep apnea). Avoid excessive alcohol (chronic heavy use suppresses testosterone in men and oestrogen in women); regular aerobic exercise increases sex hormones and improves body image and self-esteem. Sexual education normalising diverse patterns of sexual desire (responsive vs spontaneous desire models) reduces distress from expected variations in libido and prevents pathologising normal variation.

See your GP or a psychosexual therapist if: your sexual desire has significantly decreased from your previous baseline and this change is causing you personal distress or causing problems in your relationship; low libido is accompanied by other symptoms suggesting hormonal, thyroid, or mood disorders (fatigue, weight changes, mood changes, hot flushes, erectile dysfunction); you believe a medication you have recently started is causing low libido (do not stop medication without medical advice — discuss alternatives or management); you are experiencing vaginal dryness or painful intercourse alongside low libido (genito-urinary syndrome of menopause is very treatable); and if low libido is significantly impacting your quality of life. Do not hesitate to discuss sexual concerns with your GP — sexual health is an important component of overall wellbeing. Many people feel embarrassed to raise sexual health concerns but GPs are trained to discuss these issues sensitively and non-judgementally. Referral options include psychosexual therapy (for psychological and relationship factors), endocrinology (hormonal causes), gynaecology (women — menopause, pelvic issues), and urology/andrology (men — testosterone, erectile function).